Compare ACU & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | NKTX |
|---|---|---|
| Founded | 1867 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.0M | 132.8M |
| IPO Year | 1994 | 2020 |
| Metric | ACU | NKTX |
|---|---|---|
| Price | $44.80 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 8.2K | ★ 716.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $194,489,991.00 | N/A |
| Revenue This Year | $2.19 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | $22.07 | ★ N/A |
| Revenue Growth | ★ 1.56 | N/A |
| 52 Week Low | $35.31 | $1.31 |
| 52 Week High | $45.60 | $2.74 |
| Indicator | ACU | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 60.28 |
| Support Level | $42.98 | $1.95 |
| Resistance Level | $45.20 | $2.42 |
| Average True Range (ATR) | 1.17 | 0.13 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 58.22 | 80.39 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.